Susana M. Campos, MD, MPH

Articles by Susana M. Campos, MD, MPH

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Susana M. Campos, MD, MPH, clinical director, director of Educational Initiatives, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, institute physician, assistant professor of medicine, Harvard Medical School

Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

ByUrsula A. Matulonis, MD,Susana M. Campos, MD, MPH

February 25th 2026

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Key Takeaways and Closing Thoughts on ADCs

ByVK Gadi, MD, PhD,Susana M. Campos, MD, MPH,Matthew Galsky, MD,Edward B. Garon, MD, MS,Aparna R. Parikh, MD

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Emerging ADCs in Development

ByVK Gadi, MD, PhD,Susana M. Campos, MD, MPH,Matthew Galsky, MD,Edward B. Garon, MD, MS,Aparna R. Parikh, MD

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

ByVK Gadi, MD, PhD,Susana M. Campos, MD, MPH,Matthew Galsky, MD,Edward B. Garon, MD, MS,Aparna R. Parikh, MD

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Management of Emetogenicity of Antibody-Drug Conjugates

ByVK Gadi, MD, PhD,Susana M. Campos, MD, MPH,Matthew Galsky, MD,Edward B. Garon, MD, MS,Aparna R. Parikh, MD

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

ByVK Gadi, MD, PhD,Susana M. Campos, MD, MPH,Matthew Galsky, MD,Edward B. Garon, MD, MS,Aparna R. Parikh, MD

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

New Agents Push the Envelope in Ovarian Cancer

BySusana M. Campos, MD, MPH

February 10th 2019

Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.